Evaluating the Antifungal Susceptibility Pattern of Candida albicans and the Molecular Characterization of ERG11 mutation gene associated with Fluconazole Resistant Candida albicans isolates

Abstract

Introduction: Candida species produce a wide spectrum of clinical ailments, from mucocutaneous infections to life-threatening invasive disorders. The preferred treatment is to use azoles, such as fluconazole. There are multiple mechanisms for azole resistance. The first is based on the changes in the molecular configuration of the target enzyme 14α-demethylase (Erg11p) due to mutations in the encoding gene ERG11. Mutations in ERG11 and amino acid substitutions in the target enzyme ERG11 alter the enzyme's tertiary structure, affecting the ability of azole antifungals.